Lipoprotein(a) is Associated with Sarcopenia in Patients with Type 2 Diabetes: A cross-Sectional Study
Wen Wei,Fenyan Lv,Shuling Liu,Hui Cao,Ruiyu Lin,Hangju Chen,Mei Tu,Baozhen Cao
DOI: https://doi.org/10.2147/dmso.s489605
2024-11-28
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Wen Wei, 1, 2 Fenyan Lv, 3 Shuling Liu, 3 Hui Cao, 3 Ruiyu Lin, 1 Hangju Chen, 1 Mei Tu, 1 Baozhen Cao 1 1 Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, People's Republic of China; 2 The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510280, People's Republic of China; 3 Department of Endocrinology, Fujian Longyan First Hospital, Fujian Medical University, Fuzhou, 350004, People's Republic of China Correspondence: Baozhen Cao; Mei Tu, Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, People's Republic of China, Tel +86-0597-3082152 ; +86-0597-2958989, Fax +86-0597-2292374, Email ; Background: The association between lipoprotein(a) (Lp(a)) and sarcopenia in T2DM patients of general age is unclear, and whether this association differs by sex remains uncertain. We intend to analyze the association between Lp(a) and sarcopenia in patients with type 2 diabetes mellitus (T2DM) and whether this association differs by sex. Methods: T2DM patients between December 2021 and December 2022 were consecutively enrolled. Sarcopenia was defined according to the criteria of Consensus of the Asian Working Group for Sarcopenia (AWGS) 2019.A multivariable logistic regression model was used to calculate the odds ratio of Lp(a)≥ 30 mg/dL for sarcopenia in total T2DM patients and in all sexes. Restricted cubic splines were also used to evaluate the association between Lp(a) and sarcopenia. Results: Among the 426 patients, the mean age was 58.6 years and 56.3% were males. The prevalence of sarcopenia was 31.7% in total patients, 34.2% in male and 28.5% in female. The percentages of Lp(a)≥ 30 mg/dL were 19.0% in total patients. Compared with patients in Lp(a)< 30 mg/dL group, those in Lp(a)≥ 30 mg/dL group showed an increased risk of sarcopenia (adjusted odds ratio [aOR]: 2.19, 95% CI: 1.09 to 4.39, p = 0.027). Results from restricted cubic splines were robust. When analyzing each sex, there was also a significant association between Lp(a)≥ 30 mg/dL and sarcopenia (male: aOR: 2.59, 95% CI: 1.09 to 6.21, p = 0.032; female: aOR: 2.45, 95% CI: 1.06 to 6.03, p = 0.039). Conclusion: In T2DM patients, elevated Lp(a) was associated with an increased risk of sarcopenia and such an association did not differ by sex. Screening for sarcopenia should be emphasized in T2DM patients with Lp(a)≥ 30 mg/dL, both men and women. Keywords: lipoprotein(a), sarcopenia, type 2 diabetes mellitus, sex Sarcopenia is a progressive and widespread disorder associated with a reduction in muscle quantity, quality, and function. 1 The prevalence of sarcopenia is much higher in different patient groups compared to the general population. The overall prevalence has reached 20% or even higher in individuals with diabetes. 2,3 However, in most studies that reported sex, there is no significant association with sarcopenia prevalence. 4 The multiple comorbidities associated with type 2 diabetes mellitus (T2DM) (retinopathy, renal, vascular involvement, etc.) have even been directly associated with the presence of sarcopenia in diabetic patients. 5–8 Sarcopenia is also associated with poor outcomes in patients with diabetes, including cognitive impairment, infection, falls, disability, and mortality 34041847/31040938/37608605. Therefore, to find and treat modifiable risk factors of sarcopenia in diabetic patients is helpful to prevent the development and progression of sarcopenia in diabetic patients, and is of great significance to improve the quality of life of diabetic patients. Previous evidence showed that low muscle mass was associated with higher levels of triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), and remnant-like particle cholesterol (RLP-C). 9,10 On the contrary, Jiang et al indicated that an increase in TG and TC may have a protective effect on sarcopenia. 11 Furthermore, a cross-sectional analysis from UK Biobank demonstrated that sarcopenia was associated with higher concentration of HDL-C and lower values of apoprotein A and apoprotein B only in men. 12 Apoprotein B is the main component of LDL-C and VLDL-C, so low apoprotein B means low LDL-C and VLDL-C. However, the study from UK Biobank did not found a significant association between sarcopenia and LDL-C. Previous studies have shown inconsistent relationships between clinical l -Abstract Truncated-
endocrinology & metabolism